Arie Belldegrun

Arie Belldegrun (board member) discloses dealings in 5 companies, chiefly Allogene Therapeutics, Inc., UroGen Pharma Ltd. and Arno Therapeutics, Inc. In total, 16 filings cover trades dated from 12 January 2016 to 20 June 2025.

The open-market record is one-sided, with 3 purchases worth €1.7M and not one sale. The amount is not disclosed for 2 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 5 share grants and 5 option exercises.

On 1 out of 3 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

On 20 June 2025 came the latest disclosure, a transaction for €1.4M in Kronos Bio, Inc. The clock since the last published purchase (14 January 2022) now reads 1,738 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.